Updated Results from the Trastuzumab Deruxtecan (T-Dxd) 5.4 Mg/kg Triplet Combination of DESTINY-Gastric03 (DG-03): First-line (1L) T-DXd with Fluoropyrimidine (FP) and Pembrolizumab in Advanced/metastatic HER2-positive (HER2+) Esophageal Adenocarcinoma, Gastric Cancer (GC), or Gastroesophageal Junction Adenocarcinoma (GEJA).
Journal of Clinical Oncology（2025）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined